Metformine Hcl Sandoz

Metformin hydrochloride, the active ingredient in Metformine Hcl Sandoz, is a biguanide presented as an oral tablet for oral use. It treats elevated blood glucose levels in adults with type 2 diabetes mellitus. GNH USA supplies Metformine Hcl Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformine Hcl Sandoz is a biguanide used to improve glycaemic control in disorders of glucose metabolism.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. Prediabetes: helps delay progression to overt diabetes by improving insulin sensitivity. Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

Metformine Hcl Sandoz may cause a range of adverse reactions.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Metallic taste - Loss of appetite - Weight loss

Serious or Rare Side Effects: - Lactic acidosis - Severe hypoglycaemia (especially with insulin or sulfonylureas) - Vitamin B12 deficiency - Hepatic dysfunction - Skin rash or hypersensitivity reactions - Anaphylactic shock

Before prescribing Metformine Hcl Sandoz, clinicians should consider several safety aspects.

Renal function monitoring: assess eGFR before initiation and periodically. Hepatic function: avoid in patients with significant liver disease. Lactic acidosis risk: discontinue before radiographic contrast studies. Pregnancy considerations: evaluate risk‑benefit, as safety data are limited. Vitamin B12 monitoring: check levels during long‑term therapy. Store at room temperature: keep in the original container, protect from moisture and heat.

Metformine Hcl Sandoz can interact with various medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis. - Alcohol: may potentiate hypoglycaemia. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: monitor renal function and potassium. - Warfarin: may affect INR, requiring closer monitoring.